{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:26:00Z","timestamp":1760149560401,"version":"build-2065373602"},"reference-count":47,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Significant increases in antibacterial use were observed during the COVID-19 pandemic. However, subsequent analyses found this increase in antibiotic use to be excessive in comparison with the relatively low rates of bacterial coinfection. Although patients who are critically ill with COVID-19 may be at an increased risk for pulmonary aspergillosis, antifungal use in these populations remained underreported, particularly in later phases of the pandemic. This single-center, population-level cohort analysis compares the monthly use rates of mold-active antifungal drugs in the medical intensive care unit during April 2019\u2013March 2020 (baseline) with those during April 2020\u2013November 2022. The antifungal drugs included in the analysis were liposomal amphotericin B, anidulafungin, isavuconazonium, posaconazole, and voriconazole. We found that during 2020\u20132022, the usage of antifungal drugs was not significantly different from baseline for all included agents except isavuconazonium, which was used significantly more (p = 0.009). There were no changes in diagnostic modalities between the two time periods. The reported prevalence of and mortality from COVID-19-associated pulmonary aspergillosis (CAPA) may have resulted in higher rates of prescribing antifungal drugs for critically ill patients with COVID-19. Antimicrobial stewardship programs should develop and apply tools to facilitate more effective and appropriate antifungal use.<\/jats:p>","DOI":"10.3390\/antibiotics12091352","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T07:25:24Z","timestamp":1692775524000},"page":"1352","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Missed Opportunities for Antifungal Stewardship during the COVID-19 Era"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7735-1130","authenticated-orcid":false,"given":"Brandon K.","family":"Hawkins","sequence":"first","affiliation":[{"name":"College of Pharmacy, University of Tennessee Health Science Center, Knoxville, TN 37920, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1856-3357","authenticated-orcid":false,"given":"Samantha D.","family":"Walker","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Tennessee Medical Center, Knoxville, TN 37920, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud A.","family":"Shorman","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Tennessee Medical Center, Knoxville, TN 37920, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.cmi.2020.07.016","article-title":"Bacterial co-infection and secondary infection in patients with COVID-19: A living rapid review and meta-analysis","volume":"26","author":"Langford","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1017\/ice.2015.136","article-title":"Factors influencing antibiotic-prescribing decisions among inpatient physicians: A qualitative investigation","volume":"36","author":"Livorsi","year":"2015","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"ofab510","DOI":"10.1093\/ofid\/ofab510","article-title":"Coronavirus disease 2019\u2013associated invasive fungal infection","volume":"8","author":"Baddley","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/myc.13096","article-title":"COVID-19 associated pulmonary aspergillosis","volume":"63","author":"Koehler","year":"2020","journal-title":"Mycoses"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1016\/S2666-5247(20)30027-6","article-title":"Diagnosing COVID-19-associated pulmonary aspergillosis","volume":"1","author":"Verweij","year":"2020","journal-title":"Lancet Microbe"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"101752","DOI":"10.1016\/j.tmaid.2020.101752","article-title":"Invasive pulmonary aspergillosis complicating SARS-CoV-2 pneumonia: A diagnostic challenge","volume":"38","author":"Antinori","year":"2020","journal-title":"Travel Med. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.3201\/eid2607.201603","article-title":"Fatal invasive aspergillosis and coronavirus disease in an immunocompetent patient","volume":"26","author":"Blaize","year":"2020","journal-title":"Emerg. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S2213-2600(18)30274-1","article-title":"Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: A retrospective cohort study","volume":"6","author":"Schauwvlieghe","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jfma.2017.06.002","article-title":"Higher mortality of severe influenza patients with probable aspergillosis than those with and without other coinfections","volume":"116","author":"Ku","year":"2017","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1093\/cid\/ciaa007","article-title":"High rates of influenza-associated invasive pulmonary aspergillosis may not be universal: A retrospective cohort study from Alberta, Canada","volume":"71","author":"Schwartz","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"RECOVERY Collaborative Group, Chappell, L., Horby, P., Lim, W.S., Emberson, J.R., Mafham, M., Bell, J.L., Linsell, L., Staplin, N., and Brightling, C. (2021). Dexamethasone in hospitalized patients with COVID-19. New Engl. J. Med., 384, 693\u2013704.","DOI":"10.1056\/NEJMoa2021436"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"RECOVERY Collaborative Group (2021). Tocilizumab in patients admitted to hospital with COVID-19 (Recovery): A randomised, controlled, open-label, platform trial. Lancet, 397, 1637\u20131645.","DOI":"10.1101\/2021.02.11.21249258"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): A randomised, double-blind, parallel-group, placebo-controlled phase 3 trial","volume":"9","author":"Marconi","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_14","unstructured":"(2022). Tocilizumab [Package Insert], Genentech, Inc.. Available online: https:\/\/www.gene.com\/download\/pdf\/actemra_prescribing.pdf."},{"key":"ref_15","unstructured":"(2022). Baricitinib [Package Insert], Lilly USA, LLC.. Available online: https:\/\/uspl.lilly.com\/olumiant\/olumiant.html#pi."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: Executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Grau, S., Hern\u00e1ndez, S., Echeverr\u00eda-Esnal, D., Almendral, A., Ferrer, R., Lim\u00f3n, E., Horcajada, J.P., and Catalan Infection Control Antimicrobial Stewardship Program (VINCat-PROA) (2021). Antimicrobial consumption among 66 acute care hospitals in Catalonia: Impact of the COVID-19 pandemic. Antibiotics, 10.","DOI":"10.3390\/antibiotics10080943"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1186\/s13054-022-04270-z","article-title":"Impact of COVID-19 pandemic on antifungal consumption: A multicenter retrospective analysis","volume":"26","author":"Bienvenu","year":"2022","journal-title":"Crit. Care"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ajic.2020.11.015","article-title":"Stevens. Fungal superinfection in patients with COVID-19: Role of antifungal stewardship?","volume":"49","author":"Nestler","year":"2021","journal-title":"Am. J. Infect. Control"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.cmi.2022.01.027","article-title":"Defining COVID-19-associated pulmonary aspergillosis: Systematic review and meta-analysis","volume":"28","author":"Kariyawasam","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Egger, M., Bussini, L., Hoenigl, M., and Bartoletti, M. (2022). Prevalence of COVID-19-associated pulmonary aspergillosis: Critical review and conclusions. J. Fungi, 8.","DOI":"10.3390\/jof8040390"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of america","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ijid.2022.05.005","article-title":"COVID-19-associated mucormycosis: An opportunistic fungal infection. A case series and review","volume":"121","author":"Balushi","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e543","DOI":"10.1016\/S2666-5247(21)00237-8","article-title":"The emergence of COVID-19 associated mucormycosis: A review of cases from 18 countries","volume":"3","author":"Hoenigl","year":"2022","journal-title":"Lancet Microbe"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1016\/S1473-3099(20)30847-1","article-title":"Defining and managing COVID-19-associated pulmonary aspergillosis: The 2020 ECMM\/ISHAM consensus criteria for research and clinical guidance","volume":"21","author":"Koehler","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_28","first-page":"1631","article-title":"Navigating the uncertainties of COVID-19-associated aspergillosis: A comparison with influenza-associated aspergillosis","volume":"224","author":"Lamoth","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1177\/08850666211047166","article-title":"Practice guidelines for the diagnosis of COVID-19-associated pulmonary aspergillosis in an intensive care setting","volume":"37","author":"Hashim","year":"2021","journal-title":"J. Intensive Care Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13613-021-00923-4","article-title":"Risk factors for invasive aspergillosis in ICU patients with COVID-19: Current insights and new key elements","volume":"11","author":"Montrucchio","year":"2021","journal-title":"Ann. Intensive Care"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/myc.13434","article-title":"COVID-19-associated pulmonary aspergillosis (CAPA): Risk factors and development of a predictive score for critically ill COVID-19 patients","volume":"65","year":"2022","journal-title":"Mycoses"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"ofad155","DOI":"10.1093\/ofid\/ofad155","article-title":"Coronavirus disease 2019\u2013associated pulmonary aspergillosis: A noninvasive screening model for additional diagnostics","volume":"10","author":"Permpalung","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1093\/infdis\/jiu017","article-title":"Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype","volume":"209","author":"Zonios","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_34","unstructured":"Pfizer Inc (2022). VFEND (Voriconazole) Prescribing Information, Pfizer."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1086\/423275","article-title":"Voriconazole-induced QT interval prolongation and ventricular tachycardia: A non-concentration-dependent adverse effect","volume":"39","author":"Alkan","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Chu, H.Y., Jain, R., Xie, H., Pottinger, P., and Fredricks, D.N. (2013). Voriconazole therapeutic drug monitoring: Retrospective cohort study of the relationship to clinical outcomes and adverse events. BMC Infect. Dis., 13.","DOI":"10.1186\/1471-2334-13-105"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/bcpt.13465","article-title":"Voriconazole therapeutic drug monitoring in critically ill patients improves efficacy and safety of antifungal therapy","volume":"127","author":"Li","year":"2020","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1086\/319211","article-title":"Mortality and costs of acute renal failure associated with amphotericin B therapy","volume":"32","author":"Bates","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"S417","DOI":"10.1016\/j.bbmt.2016.12.505","article-title":"Comparison of posaconazole versus voriconazole in the induction of acute myeloid leukemia: Impact on cost, safety, and efficacy","volume":"23","author":"Antosz","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s12325-016-0443-1","article-title":"Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis","volume":"34","author":"Harrington","year":"2016","journal-title":"Adv. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"S175","DOI":"10.1093\/infdis\/jiaa394","article-title":"Core recommendations for antifungal stewardship: A statement of the mycoses study group education and research consortium","volume":"222","author":"Johnson","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12941-019-0323-z","article-title":"A systematic review of the impact of antifungal stewardship interventions in the United States","volume":"18","author":"Hart","year":"2019","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"106255","DOI":"10.1016\/j.ijantimicag.2020.106255","article-title":"Impact of a non-compulsory antifungal stewardship program on overuse and misuse of antifungal agents in a tertiary care hospital","volume":"57","author":"Markogiannakis","year":"2021","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/myc.12329","article-title":"Antifungal stewardship in daily practice and health economic implications","volume":"58","author":"Valerio","year":"2015","journal-title":"Mycoses"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Machado, M., Chamorro de Vega, E., Mart\u00ednez-Jim\u00e9nez, M.D.C., Rodr\u00edguez-Gonz\u00e1lez, C.G., Vena, A., Navarro, R., Zamora-Cintas, M.I., Agnelli, C., Olmedo, M., and Galar, A. (2021). Utility of 1,3 \u03b2-d-glucan assay for guidance in antifungal stewardship programs for oncologic patients and solid organ transplant recipients. J. Fungi, 7.","DOI":"10.3390\/jof7010059"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Murri, R., Lardo, S., De Luca, A., Posteraro, B., Torelli, R., De Angelis, G., Giovannenze, F., Taccari, F., Pavan, L., and Parroni, L. (2021). Post-prescription audit plus beta-d-glucan assessment decrease echinocandin use in people with suspected invasive candidiasis. Medicina, 57.","DOI":"10.3390\/medicina57070656"},{"key":"ref_47","unstructured":"National Healthcare Safety Network (2023, May 01). Chapter 14: Antimicrobial Use and Resistance (AUR) Module\u2014January 2023. Centers for Disease Control and Prevention, Available online: https:\/\/www.cdc.gov\/nhsn\/pdfs\/pscmanual\/11pscaurcurrent.pdf."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/9\/1352\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:40:02Z","timestamp":1760128802000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/9\/1352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,23]]},"references-count":47,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["antibiotics12091352"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics12091352","relation":{},"ISSN":["2079-6382"],"issn-type":[{"type":"electronic","value":"2079-6382"}],"subject":[],"published":{"date-parts":[[2023,8,23]]}}}